Company history

The company began in a shortage economy. In May 1946 a group led by Kazato Kenji started electron-microscope research in Mobara, Chiba. Kazato had been a naval technical officer, trained at the Naval Engineering College and running an anti-aircraft missile programme at the Naval Technical Research Institute; sorting his effects for demobilization he reread a 1942 Japanese book on electron microscopes, and staked on that instrument the technological gap the defeat had exposed. Some eighteen months of prototyping later, in May 1949, the group incorporated Japan Electron Optics Laboratory in Mitaka, Tokyo — thirteen people and $1,389 (¥500,000) of capital, working out of a corner of a radio laboratory lent by an old navy connection. The English name gave the company the initials it still trades under.

An electron microscope resolves structure at the nanometre scale that no optical microscope can reach, and it was indispensable to metallurgy, semiconductor materials and biology. In 1949 only a few Western makers — Siemens in Germany, RCA in the United States — could build one, and occupied Japan could barely import them. JEOL completed its JEM-1 around the time of incorporation, and in February 1950 the Ministry of International Trade and Industry named it an enterprise to be fostered. The first machines went to national universities and state institutes; the customer list was, for years, the whole of Japanese science.

The narrow base pushed the company outward early. In 1952 it entered industrial equipment with an induction-hardening machine, and in 1956 analytical instruments with a magnetic-resonance apparatus — the seed of the NMR business that became a pillar decades later. It bought its Mitaka works in 1955, opened sales offices in Marunouchi and Osaka and an agent in Paris, and in April 1956 delivered an electron microscope to the French atomic energy research institute. That single export opened the route to more than thirty countries.

The 1960s turned a laboratory into a manufacturer. In 1960 JEOL set up Sakura Seiki in Akishima and moved microscope assembly and volume production out of the parent — the standard separation a research-led venture makes when it has to build in series. In May 1961 it dropped “optics” from the name and became Nihon Denshi: no longer an optics laboratory but an electronics maker. In April 1962 it raised capital to $583,333 (¥210m) and listed on the second section of the Tokyo Stock Exchange, thirteen years after starting with half a million yen.

Eight months later it opened its first American subsidiary, and the reason was structural. An electron microscope costs tens of millions of yen and up, and what decides the sale is not the specification alone but the quality of installation, calibration and maintenance afterwards. Since the buyers were research institutes and universities in the West, JEOL had to stand where they stood. France followed in 1964, Britain and Australia in 1968; in 1971 the overseas companies were unified under the single English name JEOL Ltd.

Scale followed. The head office moved from Mitaka to Akishima in 1966, and that August the shares moved to the first section. Between 1955 and 1965 headcount went from 136 to 1,592. The product line stretched from the compact Superscope of 1961 to a one-million-volt ultra-high-voltage microscope in 1966, and in 1972 the company entered medical equipment with an automatic biochemical analyser. Twenty-three years after its founding, JEOL stood on four legs — electron microscopes and scientific instruments, industrial equipment, analytical instruments and medical equipment.

At the start of the 1970s Kazato set the goal of making JEOL’s scientific-instrument arm a specialist of the rank of Beckman or Perkin-Elmer, and decided the way there was direct selling: agents could not carry the after-sales load. The Netherlands and Sweden came in 1973, Brazil and a Liechtenstein company covering Eastern Europe in 1974, by which point eleven overseas subsidiaries were in place; Italy followed in 1984, Korea in 1994, Singapore in 1995, Germany in 1997, Taiwan in 1999. It was slow, expensive infrastructure, and it is the reason the company could later sell semiconductor equipment worldwide without building a channel from scratch.

Competition was fierce in both directions. By JEOL’s own 1973 survey it stood second in the world in transmission electron microscopes behind Philips, with roughly a quarter of the market, and first in scanning microscopes. In nuclear magnetic resonance it lost ground: pulse Fourier-transform machines from Varian, Perkin-Elmer and Bruker overtook its main line, and its own FT-NMR of 1971 went through repeated specification changes that cost it the Western market.

Then the oil crisis. Industrial production fell from late 1973 to early 1975, real GNP shrank in fiscal 1974, and the shift to floating exchange rates made export earnings unstable. JEOL judged that it was carrying more people than its sales could support and chose survival over scale, planning to go from 2,568 employees in March 1974 to 1,900 a year later — largely by hiving off operations into separate companies and seconding the staff, under an agreement with the union that preserved their conditions and standing. In 1973 Kazato had also rebuilt the top of the company, abolishing the executive committee for collegial decision-making, splitting the firm into three divisions and setting a retirement age for the presidency. Three decades on, the same exposure returned: after the 2008 crash, sales fell from ¥93.8bn to ¥83.8bn and the company posted an ordinary loss of $26.4M (¥3bn).

The recovery took a decade. Under Kurihara Gonemon, president through the crisis years, JEOL waited out the collapse in demand for costly research equipment while rebuilding the medical and industrial businesses and its cost base; a thin profit in fiscal 2009 was followed by shrinking sales in 2010 and a net loss of ¥9.05bn in 2011, before sales reached ¥104.5bn and net profit ¥4.5bn by fiscal 2017. The group was simplified along the way — subsidiaries absorbed in 2009, the NMR business spun out as JEOL RESONANCE in 2011 and folded back into the parent in 2022.

Oi Izumi, a career JEOL engineer, became president in June 2018 and in 2019 put “the turn in the seventieth year” at the centre of the mid-term plan. The logic was that scientific and measuring instruments, about seventy per cent of sales, sat in a market with a ceiling: defending a top position in electron microscopes would not, by itself, produce growth. The plan aimed to lift ordinary profit from ¥7.4bn to $91.1M (¥10bn) in three years by pointing the same technology at semiconductors, industry and medicine. JEOL co-developed a multi-beam electron-beam writer for EUV-generation photomasks with IMS of Austria, opened the Musashimurayama plant in 2021 to meet the demand, and under VISION 2030 made semiconductor metrology, industrial and medical equipment its three pillars.

The bet landed. Sales rose from ¥138.4bn in fiscal 2021 to $1.3B (¥197bn) in fiscal 2024, and operating profit roughly two-and-a-half times to $234.3M (¥36bn), carried by microscope and inspection demand at the 3nm, 2nm and 1.4nm nodes and amplified by a weak yen. In 2025 JEOL bought Japan Superconductor Technology to bring in-house the superconducting magnets that high-field NMR needs, and placed its long-built European sales network under a French holding company. Seventy-six years from an instrument Japan could not buy, the company that made it has become a supplier to the leading edge of semiconductor manufacturing.